Page 2

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Ascentage tends to $150m series C
Ascentage, based on research at University of Michigan, has increased its total funding to more than $240m after closing a $150m series C round.
Investors take another slice of Lime
The Stanford-StartX Fund-backed electric scooter and bike rental service has raised $335m in a GV-led round that also included Uber.
Precision proves effective to close $110m series B
Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.
UCL helps inject $116m into Freeline
UCL and Syncona have both returned for Freeline's series B round, which will spur clinical development of the spinout's gene therapy for haemophilia B.
Humacyte engineers $150m deal
Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.
Precision BioSciences details $110m series B
Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.
Lime sweetens $250m deal
GV is reportedly leading a funding round for Lime, a bike-sharing platform also backed by NGP Capital and the Stanford-StartX fund.
CMR Surgical strings together $100m series B
Cambridge Innovation Capital has returned after backing CMR Surgical's two-tranche $46m series A round in 2016 and 2017.

test reg